RegulationPriority Review (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia), Orphan Drug (United Kingdom), Fast Track (United States)

Structure/Sequence

Sequence Code 550935032

Source: *****

Clinical Trials associated with Pegcetacoplan

NCT07495722

/ Not yet recruitingPhase 1IIT

Safely Quenching Complement in Stroke Subjects: A Phase 1 Safety Trial

This study will include adults (ages 18-80) who have had a stroke caused by a large blood clot blocking blood flow in the brain. All patients in the study must have already had a treatment called a thrombectomy, where doctors remove the clot to help blood flow return to the brain.
The goal of this study is to test the safety of a drug called EMPAVELI (pegcetacoplan). This drug is meant to lower swelling and inflammation that can happen after blood flow returns. The hope is that it may help protect the brain from more damage and improve recovery.
People in the study will get three doses of EMPAVELI through an EMPAVELI-designed pump 0-3 hours post thrombectomy surgery and 24 and 48 hours after the initial dose. Doctors will check them with exams, blood tests, brain scans, and other tests while they are there. Patients will also have follow-up visits at 30 and 90 days to see how they are doing, per the usual standard of care.
This research is important because, even with current stroke treatments, many patients still have problems like disability. If this drug is found to be safe, it could lead to better treatments to protect the brain and help people recover more fully after a stroke.

Start Date01 Apr 2026

Sponsor / Collaborator

Columbia University

NCT07214298

/ RecruitingPhase 1/2IIT

A Phase I/II Study of Complement Inhibition in Pancreatic Ductal Adenocarcinoma

This phase I/II trial tests the effect of pegcetacoplan in combination with oxaliplatin, irinotecan, leucovorin, and fluorouracil (mFOLFIRINOX) in treating patients with pancreatic ductal adenocarcinoma (PDAC) that has spread from where it first started (primary site) to other places in the body (metastatic). Pegcetacoplan works by targeting the immune complement process, a part of the immune system that defends against bacteria and may limit tumor progression and improve the immune system's response against tumor cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Leucovorin is a drug used to lessen the toxic effects of substances that block the action of folic acid. Leucovorin is a form of folic acid. It is a type of chemoprotective agent and a type of chemosensitizing agent. Fluorouracil stops cells from making DNA and it may kill tumor cells. It is a type of antimetabolite. Giving pegcetacoplan in combination with mFOLFIRINOX may be safe, tolerable, and/or effecting in treating patients with metastatic PDAC. This trial also evaluates the effect of pegcetacoplan on the incidence of major thrombotic events and the resulting complications. Thrombosis is a common complication in patients with PDAC. Thrombosis occurs when blood clots block veins or arteries. Complications of thrombosis, such as stroke or heart attack, can be life-threatening. Giving pegcetacoplan may help prevent blood clots from forming and decrease the risk of major thrombotic events.

Start Date01 Mar 2026

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

NCT07020832

/ RecruitingPhase 3

A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Start Date01 Feb 2026

Sponsor / Collaborator

Apellis Pharmaceuticals, Inc.

100 Clinical Results associated with Pegcetacoplan

100 Translational Medicine associated with Pegcetacoplan

100 Patents (Medical) associated with Pegcetacoplan

221

Literatures (Medical) associated with Pegcetacoplan

31 Dec 2026·Hematology

Real-world clinical outcomes and treatment response in complement inhibitor experienced and naïve PNH patients prescribed pegcetacoplan in Europe and Canada

Article

Author: Panse, Jens ; Kerr, Brianne ; Hatchell, Niall ; Williamson, Sam ; Wilson, Koo ; Czech, Barbara ; Patriquin, Christopher J. ; Taylor, Yasmin ; Llamas, Juan Carlos Vallejo ; Hakimi, Zalmai

OBJECTIVES:

This study investigated outcomes and response to pegcetacoplan in complement inhibitor naïve (CI_naïve) and experienced (CI_exp) PNH patients.

METHODS:

Data were drawn from the Adelphi PNH Disease Specific Programme™, a cross-sectional survey of physicians and their patients in Canada, France, Germany, Italy, Spain, and the UK between December 2023 and April 2024. Physicians reported patient characteristics and clinical outcomes, which were used to define pegcetacoplan response. Results were stratified by prior CI prescription. Analyses were descriptive.

RESULTS:

Forty-eight physicians reported on 63 patients (CI_naïve:11; CI_exp:52). Median (IQR) age was 45.0 (33.0-55.0) years, 60.3% were male. At treatment initiation versus at survey for CI_naïve and CI_exp, respectively, median (IQR) haemoglobin levels (g/dL) were 8.0 (5.0-9.0) versus 12.0 (11.2-12.3), and 9.0 (8.0-9.2) versus 11.0 (10.2-12.0); lactate dehydrogenase levels (U/L) were 500 (350-1625) versus 250 (175-525), and 470 (290-588) versus 265 (190-379); absolute reticulocyte counts (x10⁹ /L) were 220 (151-250) versus 110 (95-140), and 212 (134-281) versus 120 (105-228). At pegcetacoplan initiation, 4.4% of patients met criteria of good-to-complete response versus 79.5% at survey.

CONCLUSIONS:

Pegcetacoplan proved effective for CI_naïve and CI_exp patients in a real-world setting, with numerically improved clinical outcomes and high response rate.

31 Dec 2026·Hematology

Switching patients with PNH from pegcetacoplan to iptacopan: a case series

Article

Author: Dingli, David ; Gurnari, Carmelo ; Maciejewski, Jaroslaw ; Sanikommu, Srinivasa ; Orland, Mark

OBJECTIVES:

Limited published data exist on switching therapy from pegcetacoplan to iptacopan in patients with paroxysmal nocturnal hemoglobinuria (PNH).

METHODS:

Three patient cases were collected from the Mayo Clinic, Cleveland Clinic, and Levine Cancer Institute.

RESULTS:

Patient 1 is a 57-year-old woman with PNH. She experienced extravascular hemolysis (EVH) while on C5 inhibitors and breakthrough hemolysis (BTH) after switching to pegcetacoplan. Patient 2 is a 37-year-old woman seeking care for PNH, who was initiated on C5 inhibitor therapy and switched to pegcetacoplan. EVH and BTH were observed while she was on C5 inhibitor therapy, and transfusions were required with both C5 inhibitor and pegcetacoplan therapy. Patient 3 is a 58-year-old man with aplastic anemia and PNH who was initiated on C5 inhibitor therapy, then switched to pegcetacoplan. He experienced both EVH and BTH.

DISCUSSION:

All three patients switched from pegcetacoplan to iptacopan, and none experienced EVH or BTH while on iptacopan. After switching to iptacopan, all three patients improved hemoglobin levels and abating transfusion requirements.

CONCLUSION:

In this case series, three patients with PNH were successfully transitioned from pegcetacoplan to iptacopan monotherapy. No patients exhibited laboratory evidence of BTH, EVH, or intravascular hemolysis after switching to iptacopan.

01 Jun 2026·American journal of ophthalmology case reports

Transient vitreous opacity following combined intravitreal injection of pegcetacoplan and faricimab-svoa in patients with neovascular age-related macular degeneration and geographic atrophy

Article

Author: Wei, Carissa ; Zhang, Ying ; Stewart, Jay M

383

News (Medical) associated with Pegcetacoplan

10 Apr 2026

·www.biospace.com

Sobi Receives Health Canada Approval for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

EMPAVELI ® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced proteinuria, stabilized kidney function and C3 deposit clearance WALTHAM, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that Health Canada has approved EMPAVELI ® (pegcetacoplan), a complement inhibitor, for the treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) to reduce proteinuria. EMPAVELI ® is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases. “Health Canada’s approval of EMPAVELI ® for the treatment of C3G or primary IC-MPGN marks an important milestone for patients and families in Canada living with these rare and serious kidney diseases,” said Bob McLay, VP, General Manager of Sobi Canada. “For many in the kidney community, there have been limited treatment options and a long wait for new therapeutic advances. This approval brings renewed hope to patients and caregivers by providing a treatment option that stabilizes kidney function, addresses the underlying disease process and is supported by strong clinical evidence. We are proud to bring this important therapy to patients in Canada and remain committed to supporting the community as access expands.” C3G and primary IC-MPGN are rare kidney diseases affecting approximately 700 patients in Canada. More than half of people living with C3G or primary IC-MPGN suffer from kidney failure within five to 10 years of diagnosis, requiring a burdensome kidney transplant or dialysis therapy. 1-3 This approval is based on positive results from the Phase 3 VALIANT study, in which EMPAVELI ® demonstrated benefits across the three key endpoints identified by the Kidney Health Initiative (KHI) C3G Trial Endpoints Working Group, including significant reduction in proteinuria (68% relative reduction in uPCR), stabilization of kidney function, and substantial clearance of C3 deposits. These positive results were recently published in The New England Journal of Medicine. 6 Sobi and its partner Apellis Pharmaceuticals, Inc. have global co-development rights for systemic pegcetacoplan. About C3 Glomerulopathy (C3G) and Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) C3G and primary IC-MPGN are rare and debilitating kidney diseases that can lead to kidney failure. Excessive C3 deposits are a key marker of disease activity, which can lead to kidney inflammation, damage, and failure. Approximately 50% of people living with C3G or primary IC-MPGN suffer from kidney failure within five to 10 years of diagnosis, requiring a burdensome kidney transplant or dialysis therapy. 1-3 Additionally, approximately 90% of patients who previously received a kidney transplant will experience disease recurrence. 4 The diseases are estimated to affect 5,000 people in the United States and up to 8,000 in Europe. 5 About the VALIANT Study The VALIANT Phase 3 study (NCT05067127) was a randomized, placebo-controlled, double-blinded, multi-center study that evaluated pegcetacoplan efficacy and safety in 124 patients who were 12 years of age and older with C3G or primary IC-MPGN. It is the largest single trial conducted in these populations and the only study to include pediatric and adult patients, with native and post-transplant kidneys. Study participants were randomized to receive pegcetacoplan or placebo twice weekly for 26 weeks. Following this 26-week randomized controlled period, patients were able to proceed to a 26-week open-label phase in which all patients received pegcetacoplan. The primary endpoint of the study was the log transformed ratio of urine protein-to-creatinine ratio (UPCR) at Week 26 compared to baseline. About EMPAVELI ® (pegcetacoplan ) EMPAVELI ® (pegcetacoplan) is a targeted C3 and C3b therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases. It is the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older approved in the United States, European Union, Canada and other countries globally. EMPAVELI ® is also approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) in Canada, the United States, European Union, and other countries globally. About the Sobi ® and Apellis Collaboration Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive non-U.S. commercialization rights for systemic pegcetacoplan. Apellis has exclusive U.S. commercialization rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy. Sobi ® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn . Contacts For details on how to contact the Sobi Investor Relations Team, please click here . For Sobi Media contacts, click here . References 1. Smith RJH, et al. Nat Rev Nephrol. 2019;15(3):129-143. 2. Servais A, et al. Kidney Int. 2012;82(4):454-464. 3. Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117. 4. Tarragón, B, et al. Clin J Am Soc Nephrol 2024; 19(8)1005-1015. 5. Data on literature consensus. 6. Fakhouri F, et al. N Engl J Med 2025;393:2210-2220 7. Nester C. et al., Clin J Am Soc Nephrol 2024 19(9):1201-1208. CONTACT: Contact: Brian Castelli, brian.castelli@sobi.com

Drug ApprovalClinical ResultPhase 3

09 Apr 2026

·pmlive.com

Biogen to acquire Apellis in $5.6bn deal

Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6bn. The deal includes two commercialised, differentiated immunology and rare disease medicines, Empaveli (pegcetacoplan) and Syfovre (pegcetacoplan injection) that will add immediate sales revenue to Biogen, increasing the company’s short and long-term revenue growth profile. In 2025, the two medicines reached a combined net sales of $689m, a figure that is expected to increase over the next two years. Empaveli has been approved by the US FDA to treat rare immune-mediated kidney diseases and PNH. Syfovre is FDA-approved for geographic atrophy secondary to age related macular degeneration, an immune-mediated retinal disease. Apellis has established US sales infrastructure and capabilities, which Biogen believes will accelerate its commercial readiness for felzartamab, a treatment for three kidney diseases currently in phase 3 trials. Cedric Francois, co-founder and CEO of Apellis, said: “With Biogen’s extensive experience with immunology and rare disease, we believe this transaction will accelerate our impact and enable us to reach more patients.” The acquisition is expected to close in the second quarter of 2026. Christopher Viehbacher, Biogen’s President and CEO, said: “The addition of Apellis expands our growth portfolio in immunology and rare disease with two approved, best-in-class medicines that complement our existing portfolio and bolsters our near-and long-term growth potential,” “We believe our combined capabilities and experience will allow us to maximise the potential of Syfovre and Empaveli, while Apellis’ talent, expertise and field capabilities will further strengthen Biogen, deepening the foundation for our growing nephrology franchise with felzartamab and serving many more patients with immune-mediated retinal disease.”

Drug ApprovalAcquisitionImmunotherapyPhase 3

06 Apr 2026

·www.fiercepharma.com

March M&A surge triggers high expectations for 2026

March went out like a lion in the biopharma industry as there were seven deals struck in a span of 12 days that were worth a combined $29 billion. The surge ramped up hopes that M&A activity will be strong in 2026. Forget March going out like a lamb. On the M&A landscape, March went out like a lion. In a flurry of activity over the last 12 days of the month, biopharma companies pulled off seven transactions each for more than $1 billion and worth a combined $29 billion in headline value. The blitz indicates to market watchers that 2026 will be a prime year for M&A and that the surge seen in the fourth quarter of 2025 was not a false alarm. “We think biotech momentum can continue throughout 2026,” analysts at Jefferies wrote in their quarterly M&A scorecard, noting that the upswing comes “despite macro uncertainty” and coincides with a 64% increase in the XBI, a stock index for U.S. biotech companies, over the last year.“We also like the breadth of Big Pharma’s appetite, which includes four $5 billion-plus deals (in the first quarter), as well as smaller $1 billion to $2 billion tuck-ins,” Jefferies added. “In theory, more large M&A activity could allow investors to put more money to work, driving secondary/IPO offerings higher.” Blockbuster buyouts Of the four $5 billion-plus deals in Q1, three came in the recent spree. Merck put up $6.7 billion to acquire Terns Pharmaceuticals and its oral leukemia candidate, TERN-701. Eli Lilly offered $6.3 billion up front, plus $1.5 billion in potential contingent value right (CVR) payments, for Centessa Pharmaceuticals and its portfolio of sleep disorder treatments. On the same day, Biogen ponied up $5.6 billion for Apellis Pharmaceuticals and its pair of approved drugs Syfovre and Empaveli.In the first quarter overall, Jefferies tracked 14 deals in the industry of at least $500 million, compared to 32 in all of 2025. At the current pace of such deals, the overall value would reach $172 billion this year compared to $111 billion in 2025. Also joining the late-March M&A run was Novartis with a deal worth $2 billion upfront, plus $1 billion in potential milestones, for Pikavation Therapeutics and its portfolio of breast cancer assets. Six days later, the Swiss pharma struck another big-money buyout, paying a headline value of $2 billion for Excellergy and its allergy candidate Exl-111.Additionally, Gilead joined the spree with a $2.2 billion acquisition of Ouro Medicines and its autoimmune asset gamgertamig, while Otsuka pulled off a $1.2 billion buyout of Transcend Therapeutics and its potential post-traumatic stress disorder treatment TSND-201.The wild run of transactions comes on the heels of a binge in late 2025, which indicated that the M&A drought was finally coming to an end. Of the industry’s nine deals worth at least $5 billion in 2025, six came in the last four months of the year.Mike Patrone, a Partner with DLA Piper who specializes in biopharma M&A, said in an interview with Fierce that the market was heating up last year before the government shutdown in October.“The government reopened and then December was one of the busiest months I think I’ve ever had,” Patrone said. “The joke was at JPM Healthcare Conference in January was that there weren’t big announcements because they had all been pulled through and hammered out and announced in December.” A confluence of factors helped facilitate the wave of M&A late last year, according to Patrone. They included the increased availability of capital throughout the year and the unchilling of the IPO markets. “When you see an IPO and a high valuation and then it trades well, that bodes well for people that invest in public biotech life sciences companies,” Patrone said. “When you see the $5 billion-plus acquisitions, the M&A exits, that bodes well also because when you’re thinking about investing in the IPO or when you’re thinking about making your venture investment in the pre-IPO companies, it gives you an idea of what type of exit valuations you could be thinking about. The psychology aspect is very big when you get into the investing side of things.” It all adds up to the biotech funding and deal environment returning to “normalcy,” Jefferies said in its Q1 report. Over the last several months, Patrone said he’s noticed “immense” competition for “the real big products and compelling technologies and pipelines.” Similarly, Jefferies analysts said that investors are still operating with a “shorter-term horizon,” pursuing “higher-conviction catalysts.” Driving many of the deals is the oncoming loss of patent protection for blockbuster products. Merck, which faces the loss of exclusivity (LOE) for Keytruda by the end of this decade, has been one of the most active wheelers and dealers, executing three acquisitions over the last 10 months, each for at least $6 billion.Patrone also traced the recent surge in activity to the last time the IPO market was booming—five years ago.“The last time the IPO markets were this busy, life sciences companies and biotech took in a ton of money both in the public space and the private space,” Patrone said. “Putting all those resources to developing their pipelines, novel technologies, coupled with great advances in—not just the science itself but how companies can bring drug to market—it’s nice to see that this point later we’re getting those fantastic readouts, we’re getting these life-changing therapies at a more frequent rate than we had been and getting the big mega-deals."

AcquisitionIPO

100 Deals associated with Pegcetacoplan

External Link

KEGG	Wiki	ATC	Drug Bank
D11613	Pegcetacoplan	B03XA	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
C3 glomerulopathy	United States	Apellis Pharmaceuticals, Inc.	07 Oct 2024
Glomerulonephritis, Membranoproliferative	United States	Apellis Pharmaceuticals, Inc.	07 Oct 2024
Geographic Atrophy	United States	Apellis Pharmaceuticals, Inc.	17 Feb 2023
Hemoglobinuria, Paroxysmal	United States	Apellis Pharmaceuticals, Inc.	14 May 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Delayed Graft Function	Phase 3	Brazil	Apellis Pharmaceuticals, Inc.	01 Feb 2026
Kidney Failure, Chronic	Phase 3	Brazil	Apellis Pharmaceuticals, Inc.	01 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	United States	Apellis Pharmaceuticals, Inc.	01 Dec 2025
Cold Agglutinin Disease	Phase 3	United States	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	Japan	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	Austria	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	Belgium	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	Canada	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	Finland	Swedish Orphan Biovitrum AB	20 Oct 2022
Cold Agglutinin Disease	Phase 3	Germany	Swedish Orphan Biovitrum AB	20 Oct 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2025	Not Applicable	Hemoglobinuria, Paroxysmal	77	Pegcetacoplan (CI-experienced patients)	vjsywbmimr(htobflpqoo) = ofdbnfoebj dnlrovvarw (zmvftmnahx ) View more	Positive	06 Dec 2025
				Pegcetacoplan (CI-naive patients)	vjsywbmimr(htobflpqoo) = vvbwwuifdf dnlrovvarw (zmvftmnahx ) View more
ASH2025	Not Applicable	Hemoglobinuria, Paroxysmal	24	Pegcetacoplan	bofeekujfk(jaqlrimxdl) = xjcmlauhha ujvhpwqwjt (tdraerlpuq ) View more	Positive	06 Dec 2025
NCT05776472 (COMPLETE, ASH2025)	Phase 4	Hemoglobinuria, Paroxysmal	200	Pegcetacoplan (with a history of aplastic anemia)	oudivkajjq(yrnnoayiij) = enoqrjbjba zprxftizfl (yrpgknmxjr, 62.0 - 118.7) View more	Positive	06 Dec 2025
				Pegcetacoplan (without a history of aplastic anemia)	oudivkajjq(yrnnoayiij) = tgjnrzyhmh zprxftizfl (yrpgknmxjr, 81.8 - 136.6) View more
ASH2025	Not Applicable	Thrombotic Microangiopathies	6	Pegcetacoplan	rqrlktxomx(ccxcdbxgbp) = aakxqtigcq mnocnxayhn (rdqxdxkjqx )	Positive	06 Dec 2025
ASH2025	Not Applicable	Hemoglobinuria, Paroxysmal	87	eculizumab	flugauoxay(iipriiifqx) = zjloaopjai jmakdptnac (kjiklqfgru ) View more	Positive	06 Dec 2025
				ravulizumab	flugauoxay(iipriiifqx) = eocnuvuvud jmakdptnac (kjiklqfgru ) View more
ASH2025	Not Applicable	Hemoglobinuria, Paroxysmal	15	Pegcetacoplan	exnrbuacar(bzefibufvv) = vnrqsrfevi mvcjykouaq (jgppsmnmzi, 1.8) View more	Positive	06 Dec 2025
				Iptacopan	exnrbuacar(bzefibufvv) = rneteuzyly mvcjykouaq (jgppsmnmzi, 2.1) View more
NCT05067127 (VALIANT, N Engl J Med) Manual	Phase 3	Glomerulonephritis, Membranoproliferative \| C3 glomerulopathy	124	Pegcetacoplan	quqtfpqwua(yhvtojylni) = yrdjqorvlh rrbuqaeecr (puklwycvcf, -74.9 to -57.2) View more	Positive	03 Dec 2025
				Placebo	quqtfpqwua(yhvtojylni) = jioxtttaej rrbuqaeecr (puklwycvcf, -8.6 to 15.9) View more
NCT05148299 (CTgov)	Phase 2	Thrombotic Microangiopathies	12	Pegcetacoplan	eqtfugjkjp(zjraudrico) = qvnuyzbplr kyusysauhn (gxbgqxkpar, 4448.067) View more	-	28 Nov 2025
NCT05067127 (VALIANT, ASN2025)	Phase 3	C3 glomerulopathy	148	Iptacopan	bprnrzbqug(grvlnqskoo) = szqnxrgtur rgamjonkjp (fizkphvkvy )	Positive	08 Nov 2025
NCT05096403 (CTgov)	Phase 3	Cold Agglutinin Disease	24	Pegcetacoplan (Pegcetacoplan Double Blind During Part A)	lukjpgnhkq = gncgyfvxiz svpxvlfzxi (ajlxwbthmw, nltuievwfb - ubpssbxyjn) View more	-	30 Oct 2025
				Placebo matching Pegcetacoplan (Placebo Matching Pegcetacoplan-Double-blind During Part A)	lukjpgnhkq = oiowmhemeq svpxvlfzxi (ajlxwbthmw, erdsypfqsy - arikmjwjbm) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis